Savara Inc. (NASDAQ: SVRA) is a Healthcare company (Biotechnology) with a market capitalization of $988M. The Maz Rating grades it against the other companies in its sector.
Savara Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.48, Savara Inc. trades at 10.5x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -96.9%, return on invested capital of -112.6% and a free cash flow yield of -13.2%. On the balance sheet: a debt-to-equity ratio of 0.29 and a current ratio of 8.55. Over the past 52 weeks the share price ranged from $4.13 to $7.01, with a beta of 0.25.
Savara Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 9 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Savara Inc. (SVRA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.37% / 30% · (Cash+Inv) / Mkt Cap (36m) 10.2% / 30% · Interest income / Revenue 50500000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 2.37% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 10.2% / 33% · Receivables / Mkt Cap (36m) 0.09% / 49% · Interest income / Revenue 50500000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 2.37% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 10.2% / 33.33% · Receivables / Mkt Cap (24m) 0.09% / 33.33% · Interest income / Revenue 50500000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 14.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 90.0% / 33.33% · Receivables / Avg Assets (4Q) 0.55% / 33.33% · Interest income / Revenue 50500000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 19.4% / 33.33% · (Cash+ST Inv) / Total Assets 83.1% / 33.33% · (Cash+Recv) / Total Assets 83.9% / 33.33% · Interest income / Revenue 50500000.0% / 5% | Fail |
No. As of September 2026, Savara Inc. (SVRA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Savara Inc. is over the AAOIFI limit on Interest income / Revenue.
About 50500000.0% of each dividend: Savara Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.